FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Lowers Rating On Shares Of Medtronic Plc To Hold From Buy

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our target to $83 from $118, 13.7x our FY 27 (Apr.) EPS view, below MDT's 10-year historical forward average of 17.6x. We trim our FY 26 EPS estimate to $5.52 from $5.65 due to lower profitability expectations and MiniMed IPO dilution. We cut our FY 27 view to $6.06 from $6.11. We downgrade shares to Hold from Buy following a mixed Q1 MedTech earnings season, with divergent performances across companies and multiple near-term headwinds, including margin pressures from rising raw material costs, supply chain challenges, and tariffs, which we think can also impact MDT. Adding to these pressures, MDT announced (May 11) the closure of its Santa Rosa, CA facility, which faced a $381M antitrust verdict in February. Also, the China business (~10% of total revenue) has been facing challenges from aggressive anti-corruption campaigns targeting health care and government volume-based procurement policies, triggering steep price cuts on medical devices, with limited near-term visibility on normalization.

Related Articles

Research

CCL Industries Target Raised To C$104 From $102, Keeps Outperform at National Bk; Notes Q1 Revs In Line, EBITDA Slightly Better, Optimistic Outlook, Layering In NCIB Assumptions

Price: $86.86, Change: $+2.40, Percent Change: +2.84%

$CCL-A.TO$CCL-B.TO
Research

Research Alert: CFRA Maintains Hold Opinion On Ads Of Honda Motor Co., Ltd

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We revise our 12-month target price to USD26 (from USD25), which implies a forward P/E of 9.7x based on our revised FY 27 (Mar.) EPS estimate of JPY423 (up from JPY297). We also initiate our FY 28 EPS estimate of JPY579. Our upward revision reflects a clearer near-term earnings trough following Honda's decisive reassessment of its automobile electrification strategy, which resulted in total EV-related losses in FY 26 but allows the company to focus on its profitable hybrid electric vehicle (HEV) and motorcycle operations. The motorcycle business continues to deliver record-high sales volumes and operating profit, supported by strong demand in India and Brazil, while the automobile business is projected to benefit from a renewed focus on HEVs, particularly in North America, where the company plans to increase production and introduce new models. Honda's sound financial foundation supports a stable dividend.

$HMC
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Humana Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $330 from $256, 21.5x our 2027 EPS estimate, a premium to HUM's five- and 10-year historical forward averages of 16.7x and 17.1x, respectively. We lift our 2026 EPS estimate by $0.12 to $8.83 and our 2027 EPS view by $0.30 to $15.34. We recently upgraded our 12-month fundamental outlook for the managed health care sub-industry to neutral from negative, with HUM and peers taking steps to improve profitability via increased medical premiums, strategic portfolio shifts/exits, and heightened focus on cost control within an elevated medical cost landscape. We anticipate that these actions may improve margins and profitability looking ahead to 2027-2028 and think valuations could gradually improve. However, we see 2026 as a challenging year, as guidance reflects significant earnings pressure from Star ratings headwinds, with adjusted EPS guidance of "at least $9.00," down almost 50% from $17.14 in 2025.

$HUM